The active component of PROVENTIL HFA (albuterol sulfate) Inhalation Aerosol is albuteraol sulfate, USP racemic α1 [(tert- Butylamino)methyl]-4-hydroxy- m -xylene-α,α'-diol sulfate (2:1)(salt), a relatively selective beta2-adrenergic bronchodilator.
PROVENTIL HFA Inhalation Aerosol is indicated in adults and children 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.
Media Articles Related to Proventil ( Inhalation)
FDA approves new treatment for inhalation anthrax
Source: Bio-terrorism / Terrorism News From Medical News Today [2016.03.22]
On Friday, March 18, the U.S. Food and Drug Administration approved Anthim (obiltoxaximab) injection to treat inhalational anthrax in combination with appropriate antibacterial drugs.
Accidental Inhalation Of Betadine During Surgery Leads To Rare Complication
Source: Cleft Palate News From Medical News Today [2013.02.25]
A routine step in preparing for cleft palate surgery in a child led to an unusual - but not unprecedented - case of lung inflammation (pneumonitis), according to a report in the The Journal of...
Memory recall, fear response influenced by breathing
Source: Ear, Nose and Throat News From Medical News Today [2016.12.09]
Breathing is not just necessary for oxygen. New research finds inhalation synchronizes brain activity linked to memory recall and fear response.
Published Studies Related to Proventil ( Inhalation)
Acute hyperkalemia associated with inhalation of a potent ENaC antagonist: Phase
1 trial of GS-9411. 
multiple doses of ENaC blocker GS-9411, in healthy participants... CONCLUSIONS: GS-9411 was well tolerated; 86.1% of treated
Evaluation of intravenous anthrax immune globulin for treatment of inhalation
Bacillus anthracis toxins can be neutralized by antibodies against protective
antigen (PA), a component of anthrax toxins. Anthrivig (human anthrax
immunoglobulin), also known as AIGIV, derived from plasma of humans immunized
with BioThrax (anthrax vaccine adsorbed), is under development for the treatment
of toxemia following exposure to anthrax spores.
Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a
phase II randomised study. 
This phase II, randomised, double-blind, multicentre study (NCT00930982)
investigated the safety and efficacy of ciprofloxacin dry powder for inhalation
(DPI) in patients with non-cystic fibrosis bronchiectasis. Adults who were
culture positive for pre-defined potential respiratory pathogens (including
Pseudomonas aeruginosa and Haemophilus influenzae) were randomised to
ciprofloxacin DPI 32.5 mg or placebo administered twice daily for 28 days (with
56 days of follow-up).
Pilot study comparing total intravenous anesthesia to inhalational anesthesia in
endoscopic sinus surgery: novel approach of blood flow quantification. 
and blood loss... CONCLUSIONS: The intraoperative blood flow, as determined by optical rhinometry,
Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. [2011.10]
CONCLUSIONS: Inhaled loxapine was generally safe and well tolerated and produced rapid improvement in agitated patients with psychotic disorders. Statistically significant differences in efficacy were found for the 10-mg dose compared with placebo, with results suggesting 5 mg may be effective. The delivery of loxapine by inhalation may provide a rapid, well-tolerated option for treating acute psychotic agitation that allows patients to avoid the aversive effects and loss of autonomy often associated with use of intramuscular medications. Further investigation of this new loxapine formulation is warranted. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00369577. (c) Copyright 2011 Physicians Postgraduate Press, Inc.
Clinical Trials Related to Proventil ( Inhalation)
Controlled, 12-Week Study of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Asthmatic Patients [Terminated]
This 12-week clinical study evaluates the safety and efficacy of Albuterol Sulfate HFA
Inhalation Aerosol (Albuterol-HFA, or: A004), Armstrong's proposed HFA formulation of
metered dose inhaler (MDI) of Albuterol (Treatment T), in comparison with:
1. Placebo control: (HFA propellant only, Treatment P); and
2. Active control: 3M/Key's Proventil-HFA (Treatment R).
The treatments will be given as self-administered oral inhalations in adult and adolescent
patients with mild-to-moderate asthma, for 12-weeks. Dosing regimen throughout the 12-week
study is two actuations four times daily (QID).
Testing Potential Synergistic Effects of Albuterol and Caffeine on Metabolic Rate [Completed]
Preterm Infant Inhaled Albuterol Dosing [Recruiting]
The purpose of this study is to help determine the best dose of albuterol in premature
babies at risk of developing bronchopulmonary dysplasia (BPD). BPD is the chronic lung
disease of prematurity and is associated with increased morbidity and mortality, longer
hospital stays, and increased healthcare utilization. Albuterol is an inhaled medication
frequently used in premature infants with chronic lung disease and in people with asthma. It
is believed to be safe, but the optimal dose for infants is not clear. The investigators
hypothesize that albuterol may help a subset of premature infants with lung disease, but
they need to determine the best dose prior to doing research about how effective it is for
chronic lung disease/BPD. Response to each of three doses of albuterol will be measure using
pulmonary function tests.
Single-Dose Cross-Over Study of the Effects of Albuterol-HFA in Exercise Induced Bronchoconstriction [Terminated]
This clinical study will evaluate and establish the protective effects of Amphastar's
Albuterol Sulfate HFA Inhalation Aerosol (Albuterol-HFA), in preventing exercise-induced
bronchoconstriction (EIB) in adolescent and adult asthmatic patients, in comparison with (1)
Proventil®-HFA (Reference drug and Active Control ), and (2) Placebo-HFA control (HFA
propellant only). Safety of the test drug, Albuterol-HFA, will also be evaluated in
comparison to the Active and Placebo Controls. Analyses will be performed to determine if
the Armstrong's Albuterol-HFA has resulted in a significant bronchoprotective effect, with
attenuated Max % Fall in FEV1, in comparison to the Placebo-HFA control.
Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients [Completed]
This is a multicenter, randomized, double-blind, double-dummy, placebo-controlled,
single-dose, 5-treatment, 5-period, 5-way crossover study in pediatric patients with
persistent asthma. The primary purpose of this study is to compare the efficacy and safety
of Albuterol Spiromax with that of ProAir HFA in pediatric asthma patients at 2 delivered
dose levels equivalent to 90 mcg and 180 mcg of albuterol base.
Reports of Suspected Proventil ( Inhalation) Side Effects
Product Quality Issue (29),
Drug Dose Omission (25),
NO Adverse Event (21),
Drug Ineffective (15),
OFF Label USE (3),
NO Therapeutic Response (3), more >>
Page last updated: 2016-12-09